competition and substitutability in the swedish pharmaceuticals market substitution possibilities between brand name pharmaceuticals are analysed the analysis is based on data from three different markets the prescription drug market for beta blocking agents the over the counter market for purgatives and the hospital market for two pharmaceutical treatments for gastric ulcers the results indicate that there exist some substitution possibilities among the brand name drugs included in the study

power in firm networks what it means for regional innovation systems christopherson s clark j 2007 power in firm networks what it means for regional innovation systems regional studies 41 1223 1236 the role of power within regional firm networks is noted in empirical studies but insufficiently theorized it is suggested that network functioning is conflictual and that more powerful network members particularly transnational corporations tncs leverage regional resources to advance their sustainable competitive advantage the agendas and power exercised by tncs within regionalized firm networks have significant implications for regional policy and the uneven allocation of resources and capacities within and among regions the findings indicate that transnational firm access to resources that are critical to innovation including university research and skilled labour negatively affects the potential for innovation by small and medium size firms christopherson s et clark j 2007 le pouvoir au sein des reseaux d entreprise son importance pour les systemes d

patient or physician oriented marketing what drives primary demand for prescription drugs abstract the authors analyze primary demand effects of marketing efforts directed at the physician detailing and professional journal advertising versus marketing efforts directed at the patient direct to consumer advertising the analysis covers 86 categories or approximately 85 of the u s pharmaceutical market during the 2001 2005 period primary demand effects are rather small in contrast with the estimated sales effects for individual brands by using a new brand level method to estimate primary demand effects with aggregate data the authors show that the small effects are due to intense competitive interactions during the observation period but not necessarily to low primary demand responsiveness in contrast with previous studies the authors also find that detailing is more effective in driving primary demand than direct to consumer advertising a category sales model cannot provide such insights in addition a category sales model likely produces biased predictions about period by perio

estimating the effects of global patent protection in pharmaceuticals a case study of quinolones in india under the trips agreement wto members are required to enforce product patents for pharmaceuticals the debate about the merits of this requirement has been extremely contentious many low income economies claim that patent protection for pharmaceuticals will result in substantially higher prices for medicines with adverse consequences for the health and well being of their citizens on the other hand research based global pharmaceutical companies argue that prices are unlikely to rise significantly because most patented products have therapeutic substitutes in this paper we empirically investigate the basis of these claims central to the ongoing debate is the structure of demand for pharmaceuticals in poor economies where because health insurance coverage is so rare almost all medical expense are met out of pocket using a detailed product level data set from india we estimate key price and expenditure elasticities and supply side parameters for the fluoroquinolones sub segment of the systemic anti bacterials i e antibiotics segment of the indian pharmaceuticals market we then use these estimates to carry out counterfactual simulations of what prices profits and consumer welfare would have been had the fluoroquinolone molecules we study been under patent in india as they were in the u s at the time our results suggest that concerns about the potential adverse welfare effects of trips may have some basis we estimate that in the absence of any price regulation or compulsory licensing the total annual welfare losses to the indian economy from the withdrawal of the four domestic product groups in the fluoroquinolone sub segment would be on the order of u s 450 million or about 73 of the sales of the entire systemic anti bacterials segment in 2000 of this amount foregone profits of domestic producers constitute roughly 50 million or 11 the overwhelming portion of the total welfare loss therefore derives from the loss of consumer welfare in contrast the profit gains to foreign producers in the absence of any price regulation are estimated to be only around 53 million per year

cross national price differences for pharmaceuticals how large and why bilateral drug price and quantity indexes based on comprehensive data for seven countries us canada france germany italy japan and the uk refute the conventional wisdom that us drug prices are much higher than elsewhere for laspeyres us weighted indexes previous drug price comparisons are biased by unrepresentative samples and unweighted indexes quasi hedonic regression shows that cross national price differences reflect differences in product characteristics and in their implicit prices which reflect the regulatory regime strict price regulation systematically lowers prices for older molecules and globally diffused molecules generic competition lowers prices in less regulated regimes which also have more price elastic demand

the origins and dynamics of production networks in silicon valley abstract computer systems firms in silicon valley are responding to rising costs of product development shorter product cycles and rapid technological change by focusing and building partnerships with suppliers both within and outside of the region well known firms like hewlett packard and apple computers and lesser known ones like silicon graphics and pyramid technology are organized to combine the components and sub systems made by specialist suppliers into new computer systems as these firms collaborate to both define and manufacture new systems they are institutionalizing their capacity to learn from one another three cases a contract manufacturer a silicon foundry and the joint development of a microprocessor illustrate how inter firm networks help account for the sustained technological dynamism of the regional economy

path dependence research in regional economic development cacophony or knowledge accumulation henning m stam e and wenting r path dependence research in regional economic development cacophony or knowledge accumulation regional studies the concept of path dependence has gained momentum in the social sciences particularly in economic geography this paper explores the empirical literature on path dependence and path creation in regional economic development it offers a critical reflection on these studies and outlines commonalities and problems in research designs and empirical testing the review suggests that the popularity of the path dependence concept in regional studies has led to a cacophony of studies rather than to a purposeful accumulation of knowledge around the concept gaps are identified and guidelines are suggested for future research on path creation and path dependence in regional development henning m stam e and wenting r

consumption externalities and diffusion in pharmaceutical markets antiulcer drugs we examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a therapeutic class of drugs externalities emerge when use of a drug by others affects its value and or conveys information about efficacy and safety to patients and physicians this can affect the rate of market diffusion for a new entrant and can lead to dominance of one drug despite the availability of close substitutes we use data for h2 antagonist antiulcer drugs to estimate a dynamic demand model and quantify these effects the model has three components an hedonic price equation that measures how the aggregate usage of a drug as well as conventional attributes affect brand valuation equations relating equilibrium market shares to quality adjusted prices and marketing levels and diffusion equations describing the dynamic adjustment process we find that consumption externalities influence both valuations and rates of diffusion and that they operate at the brand and not the therapeutic class level

competition in off patent drug markets issues regulation and evidence in recent years health insurers have placed a great deal of emphasis on the ability of generic medicines to deliver significant savings to overstretched health care budgets due to their lower cost and potential for a more efficient resource allocation in this paper we study market developments after patent expiry whether health insurance captures the financial benefits from cheaper generics and whether regulation and product differentiation among others have any power in explaining originator and generic price movements generic entry and diffusion we find that health insurance does not capitalize fully or fast enough on the cost advantage of generic medicines either because generic policies do not encourage their fast uptake or because generic drug prices are high and frequently tied directly or indirectly to originator drug prices we also find that reference pricing a particular form of reimbursement regulation encourages generic entry and reduces generic prices but only marginally finally in generic markets characterized by homogeneous products we find evidence of product differentiation which is impacting prices upwards rather than downwards if health insurance is to benefit fully from generic medicines it ought to encourage faster uptake and price competition and discourage price fixing regulation that ties generic prices to those of originator brands panos kanavos joan costa font and elizabeth seeley

pharmaceutical price controls and entry strategies abstract this paper finds that the use of price controls has a statistically and quantitatively important effect on the extent and timing of the launch of new drugs firms headquartered in countries that regulate price reach fewer markets than those in countries without price controls companies avoid price controlled markets and are less likely to introduce products in additional markets after entering a price controlled country launches into low price european countries are further delayed following legalization of parallel imports the results suggest that price regulation in one country affects entry into other countries and may affect the strategies of domestic firms

protection and the product line monopoly and product quality the product line decision of a monopolist is analyzed and used to study the effect of specific and ad valorem taxes on the entire product line while specific taxes or quotas raise average quality ad valorem taxes may not the welfare consequences of such policies when the monopolist is a home one and when he she is a foreign one are discussed with a home monopolist both specific and ad valorem subsidies are welfare improving while with a foreign monopolist their welfare properties depend on the distribution of consumers copyright 1990 by economics department of the university of pennsylvania and the osaka university institute of social and economic research association

mergers with differentiated products the case of the ready to eat cereal industry traditional merger analysis is difficult to implement when evaluating mergers in industries with differentiated products i discuss an alternative which consists of demand estimation and the use of a model of postmerger conduct to simulate the competitive effects of a merger i estimate a brand level demand system for ready to eat cereal using supermarket scanner data and use the estimates to 1 recover marginal costs 2 simulate postmerger price equilibria and 3 compute welfare effects under a variety of assumptions the methodology is applied to five mergers two of which occurred and for which i compare predicted to actual outcomes

exploring the locus of invention the dynamics of network communities and firms invention productivity departing from prior research analyzing the implications of social structure for actors outcomes by applying either an ego network or a global network perspective this study examines the implications of network communities for the invention productivity of firms network communities represent dense and nonoverlapping structural groups of actors in a social system a network community lens helps identify new ways to study firms access to diverse knowledge inputs in a dynamic system of interorganizational relationships specifically we examine how the membership dynamics of a network community affect the invention productivity of member firms by either enabling or constraining access to broad diverse knowledge inputs our findings suggest first that a firm reaps the greatest invention benefits in a network community with moderate levels of membership turnover second a firm attains the greatest invention productivity when its own rate of movement across different network communities is moderate third we find that community members located in the core of their network community can benefit more from membership dynamics and prior community affiliations than those on its periphery in empirical analyses we use the evolving community structure of the network of interorganizational partnerships in the global computer industry over 1981 2001 to predict firms patenting rates

characteristics of demand for pharmaceutical products an examination of four cephalosporins we model demand for four cephalosporins and compute own and cross price elasticities between branded and generic versions of the four drugs we model demand as a multistage budgeting problem and we argue that such a model is appropriate to the multistage nature of the purchase of pharmaceutical products in particular the prescribing and dispensing stages we find quite high elasticities between generic substitutes and also significant elasticities between some therapeutic substitutes

dynamics of pro market institutions and firm performance we analyze how pro market institutions affect firm performance in emerging markets integrating transaction costs and signaling theory we advance three arguments first we separate four dynamic components of pro market institutions intensifying and fading pro market reforms and intensifying and fading pro market reversals second we propose an asymmetric dynamic view whereby not only intensifying reforms but also fading reversals improve firm performance while not only fading reforms but also intensifying reversals reduce performance finally we argue that more efficient firms perform better under each of the dynamics we test these arguments on a sample of 1092 firms from 34 emerging markets during 1998 2011

dealer price discrimination in new car purchases evidence from the consumer expenditure survey this paper documents the variation in dealer discounts for new cars using transactions price data from the consumer expenditure survey consumer specific characteristics fail to explain dealer discounts whereas model market specific and purchase transaction variables e g first time purchase trade in and financing through dealer do explain them the results contradict earlier findings of race and gender discrimination based on a controlled experiment this contradiction is reconciled by examining the higher moments of the empirical discount distribution while mean and median markups do not vary by race and gender minority purchases are characterized by higher dispersion this may rationalize the disparate treatment of minorities by dealers documented in the controlled experiment

from free entry to patent protection welfare implications for the indian pharmaceutical industry abstract there has been fierce debate over the imposition of stronger intellectual property rights laws for pharmaceutical products in developing countries this paper uses data from the indian pharmaceutical industry to develop a structural model of demand supply and entry the estimation yields demand and supply parameters that indicate significant heterogeneity among firms both within and across different therapeutic segments the estimated parameters are used to simulate patent enforcement and price deregulation for 43 drugs which predicts large losses for consumers and relatively small gains in profits for the global patent holders

regulation and pricing of pharmaceuticals reference pricing or price cap regulation we study the relationship between regulatory regimes and pharmaceutical firms pricing strategies using a unique policy experiment from norway which in 2003 introduced a reference price rp system called index pricing for a sub sample of off patent pharmaceuticals replacing the existing price cap pc regulation we estimate the effect of the reform using a product level panel dataset covering the drugs exposed to rp and a large number of drugs still under pc regulation in the time before and after the policy change our results show that rp significantly reduced both brand name and generic prices within the reference group with the effect being stronger for brand names we also identify a negative cross price effect on therapeutic substitutes not included in the rp system in terms of policy implications the results suggest that rp is more effective than pc regulation in lowering drug prices while the cross price effect raises a concern about patent protection

technological discontinuities and flexible production networks the case of switzerland and the world watch industry abstract the twentieth century history of the swiss watch industry illustrates how cultures and industrial production systems experience great difficulty adapting to external change at different points in time the current emphasis on production networks unique reservoirs of potential technological innovation realized through cooperation rather than competition among firms lacks a detailed appreciation of historic networks and in particular their fragile character in times of economic turmoil while networks can and do promote innovation within an existing technological framework historical experience suggests their fragmented atomistic structure is subject to disorganization and disintegration during periods of technological change an exclusive focus on production ignores other constraints that are powerful forces governing the reaction abilities of regions previous research has largely relied on a model of oligopolistic competition to explain how the swiss lost control of the world watch industry i conclude on the contrary that the swiss experience must be understood from the standpoint of how technological change challenges previous ways of organizing production industry culture and society technology shifts present a series of strategic turning points that industrial leaders must navigate during a period of technological change

oligopolistic competition and international trade quantity and quality restrictions abstract we examine trade restrictions such as quantity and quality limitations on imports in an oligopolistic industry consisting of foreign and domestic firms we find that the effects of trade policy hinge on the location of the quality produced by the firms in the quality spectrum a quota leads to positive protection while minimum quality standards leads to negative protection furthermore minimum standards lower national welfare and a quota has an ambiguous effect on welfare

cut throat fringe competition in an emerging country market tax evasion or the absence of market power brazil s established soft drink firms recently lost ground to multiple low price entrants with small scale operations and minimal advertising while incumbents attributed such undercutting to entrants lower costs from non compliance with the law generics counterargued that incumbents high prices stemmed from unilateral market power rather than cost heterogeneity by estimating a structural model i can single handedly explain established brands high prices through low equilibrium price elasticities of demand tax evasion in the fringe while plausible appears to be offset by higher procurement costs or less efficient scale more generally a competitive informal sector can alleviate the allocative distortions in certain concentrated industries

reference pricing competition and pharmaceutical expenditures theory and evidence from a natural experiment abstract we study the impact of regulation on competition between brand names and generics and pharmaceutical expenditures using a unique policy experiment in norway where reference pricing rp replaced price cap regulation in 2003 for a sub sample of off patent products first we construct a vertical differentiation model to analyze the impact of regulation on prices and market shares of brand names and generics then we exploit a detailed panel data set at product level covering several off patent molecules before and after the policy reform off patent drugs not subject to rp serve as our control group we find that rp significantly reduces both brand name and generic prices and results in significantly lower brand name market shares finally we show that rp has a strong negative effect on average molecule prices suggesting significant cost savings and that patients copayments decrease despite the extra surcharges under rp

financial market reactions following technological discontinuities a non event study in two industries a large body of literature has explored the challenges of technological change for established firms much of this work has focused on factors internal to firms such as inertial routines or managers cognitive limitations that constrain incumbents development of new capabilities and response to new technologies but institutional pressures arising from financial markets and the securities analysts who mediate such markets likely also play a role in whether and how incumbent firms respond to technological change we know little about how financial markets and securities analysts react as an incumbent firm is faced with a radical technological discontinuity that threatens to substitute for the existing technology understanding such reactions is critical as they further influence whether and how incumbents respond to technological discontinuities in this article i explore securities analysts reactions to incumbent firms faced with technological discontinuities in two industries digital technology in photography and voice over internet protocol voip technology in wireline telecommunications i find that these discontinuities go largely unmentioned in analysts reports and appear to have little influence on analysts recommendations or stock prices even for several years the findings suggest further that analysts and investors continue to reward incumbents for cash flows arising from focusing on the existing business and technology despite the increasing certainty of technological obsolescence copyright 2008 oxford university press

generic entry price competition and market segmentation in the prescription drug market abstract this paper studies the effects of generic entry on post patent price competition for 18 prescription drugs recently exposed to competition an independent validating test of the generic competition paradox is conducted using a newly created data set each generic entrant is associated with an average 1 increase in the branded price the one way error component model accounts for intermolecular competition market segmentation and endogeneity of entry and finds branded prices increasing by 2 alternative definitions of entry suggest that price competition is confined to the generic market the unique payer type feature of the data offers empirical evidence supporting market segmentation

tariffs vs quotas under duopoly of heterogeneous goods abstract this paper analyzes a model of duopoly with heterogeneous goods where behavior patterns are endogenously determined by producers it is shown that the source of non equivalence of tariffs and quotas is not the monopolistic behavior of the domestic producer over consumers but a certain kind of his behavior against the foreign producers this result is then extended to the cases of a general nash type oligopoly and monopolistic competition the paper also examines how the behavior patterns of the producers are affected by tariffs and quotas and proves non equivalence of tariffs and quotas in the duopoly situation where the pricing behavior of the producers is endogenously determined by trade policies

trade policy and its impact on quality of imports this paper examines the role of trade policies in influencing a foreign monopolist s decision on price quantity and in particular the quality of its product we show that a specific tariff leads to higher quality whereas an ad valorem tariff usually does the opposite quotas and specific tariffs are shown to be equivalent and both dominate an ad valorem tariff in terms of welfare we also show that subjecting imports to minimum quality requirements hampers national welfare finally we present a comprehensive ranking of all the policy instruments considered in this paper

impact of direct to consumer advertising on pharmaceutical prices and demand author affiliation dhaval dave ddave bentley eduhenry saffer hsaffer gc cuny edu acknowledgment this research was supported by a grant from the agency for healthcare research and quality to the national bureau of economic research the authors are grateful to gregory colman robert feinberg michael grossman dominic hodgkin rick smith and two anonymous reviewers for valuable comments li ma and zhen ma provided excellent research assistance 1 introductionbetween 1995 and 2007 expenditures on prescription drugs increased by 274 raising the drug related share of total health care spending from 6 to over 10 and making it one of the fastest growing components of health care costs 1 the growth in prescription drug expenditures has coincided with the growth in pharmaceutical promotion which increased from 11 4 billion in 1996 to 29 9 billion in 2005 donohue cevasco and rosenthal 2007 promotion of prescription drugs is generally limited to patented drugs and includes direct to consumer advertising dtca on broadcast and print media as well as direct to physician promotion dtpp through visits by company representatives to physician offices known as detailing free samples provided to physicians and advertising in professional journals the largest increase in promotion resulted from the expansion of dtca into broadcast media this expansion was precipitated by the food and drug administration s fda s clarification of the rules governing broadcast advertising in 1997 and 1999 making it feasible for companies to promote via television and radio advertisements dtca spending increased from 150 million in 1993 to 4 24 billion in 2005 these new regulations which allow broadcast dtca remain a controversial policy currently only the united states and new zealand permit such advertising dtca is facing increased scrutiny from congress and consumer groups congressional leaders have contended that dtca raises prescription drug costs and have requested that the policy be revisited 2 some groups maintain that the recent increases in dtca are responsible for the increases in expenditures on prescription drugs the national institute for health care management november 2001 claimed that increases in sales for the 50 most heavily advertised drugs caused 47 8 of the increase in expenditures on prescription drugs growth in prescription drug spending is broadly driven by increases in utilization and price and shifts in the composition of drugs being used all of which may be impacted by dtca dtca can raise the demand for existing drugs and can also affect their price elasticity the increase in demand can be beneficial if it improves adherence donohue et al 2004 bradford et al 2006 or makes individuals aware of the existence of drug therapies for their health conditions expenditures have also increased in part as a result of the fact that newer drugs generally cost more than older drugs and dtca might induce substitution to these newer more expensive drugs which also tend to be more heavily advertised this may be health promoting since newer drugs have been shown to be more effective in improving health than are older drugs lichtenberg and virabhak 2007 treatment through prescription drugs can also be more cost effective than alternative and more intensive therapies inducing some substitution among these forms of care 3 a key component of this question of the extent to which the growth in dtca has contributed to rising prescription drug costs relates to how dtca affects drug prices to the best of our knowledge no prior studies have investigated the impact of dtca on prescription drug prices on a broad scale this study adds to the literature with an empirical investigation of the role of prescription drug promotion in affecting the price of prescription drugs prior studies which have explored the effects of consumer advertising on sales have also generally utilized older data collected prior to 2000 have not differentiated between broadcast and non broadcast dtca and have arrived at mixed conclusions regarding the impact of total dtca on own sales

new car sales and used car stocks a model of the automobile market this article develops a short run general equilibrium model of the automobile market by combining a discrete choice model of consumer automobile demand with simple models of new automobile production and used vehicle scrappage the theoretical model allows an unlimited degree of heterogeneity of both consumers and automobiles with equilibrium defined as aggregate demand equal to supply for every vehicle type econometric estimates of the scrappage and demand functions are then used to create a simulation model of the automobile market which is used to provide forecasts of automobile sales stocks and scrappage for the 1978 1990 period

the demand for ethanol as a gasoline substitute abstract this paper estimates household preferences for ethanol e85 as a gasoline e10 substitute i develop a theoretical model linking the shape of the ethanol demand curve to the underlying distribution among households of willingness to pay for ethanol i estimate the model using instrumental variables techniques and data from many retail fueling stations i find that a 0 10 per gallon increase in ethanol s price relative to gasoline leads to a 12 16 decrease in the quantity of ethanol demanded my findings imply that preferences for ethanol are heterogeneous and that a substantial fraction of households are willing to pay a premium for the fuel this reduces substantially the simulated efficiency cost of an ethanol content standard since some households choose ethanol without large subsidies mitigating deadweight losses

does regulation drive out competition in pharmaceutical markets abstract most countries regulate pharmaceutical prices either directly or indirectly on the assumption that competition is at best weak in this industry this paper tests the hypothesis that regulation of manufacturer prices and retail pharmacy margins undermines price competition we use data from seven countries for 1992 to examine price competition between generic competitors different manufacturers of the same compound and therapeutic substitutes similar compounds under different regulatory regimes we find that price competition between generic competitors is significant in unregulated or less regulated markets united states united kingdom canada and germany but that regulation undermines generic competition in strict regulatory systems france italy and japan regulation of retail pharmacy further constrains competition in france germany and italy regulation thus undermines the potential for significant savings on off patent drugs which account for a large and growing share of drug

exchange rates and traded goods prices abstract this paper presents a partial equilibrium model of the determination of domestic and export prices by a monopolistic competitive firm the model stresses the role of exchange rate uncertainty and expectations the most important result of the analysis is that the stochastic properties of deviations from the law of one price are crucially affected by the currency of denomination of export prices using data on domestic and dollar export prices of japanese goods i find that deviations from the law of one price are due to exchange rate surprises but also to price staggering and ex ante price discrimination

absorptive capacity and localized spillovers focal firms as technological gatekeepers in industrial districts despite the diffusion of communication tools and boundary spanning technologies knowledge flows in innovation processes retain a distinct localized nature in many industries and geographical clusters emerge as critical areas to foster technological diffusion in this article we focus on the knowledge mediating role as technological gatekeepers of focal firms in industrial districts based on a longitudinal dataset of 720 patents granted by the united states patent and trademark office uspto between 1990 and 2003 to firms in the automatic packaging machinery industrial district in northern italy and controlling for the uneven geographical distribution of patenting activities we show that i firms within the district use local knowledge to a greater extent and more rapidly than knowledge from outside the district ii focal firms use external knowledge to a greater extent than other firms operating in the district and iii other nonfocal firms within the district rely on knowledge generated by focal firms to a greater extent than would be expected given the geographic distribution of innovative activity in the industry implications for research on innovation in localized economic systems and firm level strategic differentiation are discussed copyright 2012 the author 2011 published by oxford university press on behalf of associazione icc all rights reserved oxford university press

generics and new goods in pharmaceutical price indexes drug prices and their rate of inflation are a major focus of current policy debates on u s health care in this paper we show that where patent expiration and generic entry are significant as they are for many important classes of drugs movements in the official price indexes may be poor indicators of the actual prices paid and the resulting changes in consumer welfare when a drug goes off patent those consumers who regard the branded and generic versions as more or less perfect substitutes experience a substantial price decline and concomitant welfare gain which the current methods used by the statistical agencies fail to capture we suggest a number of alternative ways of proceeding although our computations are based on a limited number of cases they imply that the overall rate of inflation in drug prices may be quite seriously overstated while generic pharmaceuticals are the topic of our calculations the problem discussed is also of wider importance generic drugs are a special and possibly easy case

the influence of managed care on generic prescribing rates an analysis of hmo physicians retail expenditures on prescription drugs continue to grow annually by double digits while the share of prescriptions dispensed as generics remains relatively constant efforts to curtail rising drug expenditures have been exhibited by managed care organizations mcos yet drug expenditures continue to rise using the national ambulatory medical care survey namcs for 1997 2000 this study examines how managed care specifically health maintenance organizations hmos influence the physician s decision to prescribe the generic version of a multi source drug the findings show that hmo physicians are not significantly more likely to prescribe generic drugs than non hmo physicians among hmo physicians different cost reduction tools effect generic prescribing behaviour in different ways with the size of the effect depending on the patient and physician relationship with the hmo

the potential impact of tobacco biopharming the case of human serum albumin biopharming stands to significantly expand the uses of many agricultural crops this article examines the potential size and distribution of welfare gains from biopharming transgenic tobacco as a source of human serum albumin hsa using an economic surplus model under imperfect competition the results suggest that hsa from transgenic tobacco will generate annual profits for the innovating firm of between 25 million and 49 million on the other hand consumers are unlikely to benefit during the patent life of the product given the innovator s market power

regulation and competition in the taiwanese pharmaceutical market under national health insurance this article investigates the determinants of the prices of pharmaceuticals and their impact on the demand for prescription drugs in the context of taiwan s pharmaceutical market where medical providers earn profit directly from prescribing and dispensing drugs based on product level data we find evidence that the profit seeking behavior of the medical providers in the prescription drug market transfers the force of competition from the unregulated wholesale market to the regulated retail market and hence market competition still plays an important role in the determination of the regulated price we also find that the profit seeking behavior plays a similar role to advertising in that it increases the brand loyalty and hence lowers price elasticity an important implication of our study is that the institutional features in the pharmaceutical market matter in shaping the nature of pharmaceutical competition and the responsiveness of pharmaceutical consumption with respect to changes in price

alfred marshall lecture intellectual property rights protection in developing countries the case of pharmaceuticals patent enforcement in developing countries generates considerable controversy especially when patents involve potentially life saving drugs this paper argues that common concerns regarding the effects of patents on prices and on research incentives of pharmaceutical multinationals are misplaced rather the most significant effects are likely to concern access to patented drugs in poor countries because prices in developing countries are much lower than in the developed world multinationals may choose to enter such markets with a delay or not at all implying a complete loss of access to patented drugs in developing countries even when multinationals enter countries like india their marketing and distribution networks are not currently built out leading to limited access within the country such considerations may provide a justification for policies targeting access in the short and medium run such as compulsory licensing

price competition in pharmaceuticals the case of anti infectives a fundamental question in industrial organization regards the relationship between price and the number of sellers this relationship has been particularly important in the pharmaceutical industry where legislative changes were specifically designed to foster competition previous research on the pharmaceutical industry has shown generic entry has a mixed impact generic prices fall rapidly with generic entry whereas branded prices tend to increase or decrease only slightly using more complete data focused on one segment of the pharmaceutical industry anti infectives we find that the relationship between pharmaceutical prices and the number of sellers is more like that found in other industries jel l11 l65 d4

demand estimation and merger simulations for drugs logits v aids abstract we use adhd drugs sales data from 2000 2003 and compare estimates of elasticities and merger simulations from three different demand models models include logit random coefficients logit and conditional aids demand model with multistage budgeting the magnitude of cross price elasticities is larger in the third model in comparison to the first two and some of the cross price elasticities are estimated to be negative hypothetical merger simulations show larger price effects for the multistage aids model in comparison to the discrete choice models

by ounce or by calorie the differential effects of alternative sugar sweetened beverage tax strategies the obesity epidemic and excessive consumption of sugar sweetened beverages have led to proposals of economics based interventions to promote healthy eating in the united states targeted food and beverage taxes and subsidies are prominent examples of such potential intervention strategies this paper examines the differential effects of taxing sugar sweetened beverages by calories and by ounces on beverage demand to properly measure the extent of substitution and complementarity between beverage products we developed a fully modified distance metric model of differentiated product demand that endogenizes the cross price effects we illustrated the proposed methodology in a linear approximate almost ideal demand system although other flexible demand systems can also be used in the empirical application using supermarket scanner data the product level demand model consists of 178 beverage products with combined market share of over 90 the novel demand model outperformed the conventional distance metric model in non nested model comparison tests and in terms of the economic significance of model predictions in the fully modified model a calorie based beverage tax was estimated to cost 1 40 less in compensating variation than an ounce based tax per 3 500 beverage calories reduced this difference in welfare cost estimates between two tax strategies is more than three times as much as the difference estimated by the conventional distance metric model if applied to products purchased from all sources a 0 04 cent per kcal tax on sugar sweetened beverages is predicted to reduce annual per capita beverage intake by 5 800 kcal

synchronizing export orientation with import substitution creating competitive indigenous high tech companies in china summary this paper examines how the synergy between china s domestic and the international market has affected its most competitive indigenous companies through case study in china s ict sectors in the 1990s the paper shows that when export upgrades and domestic market growth intersect in timing and sectors that is when they synchronize chinese companies found conditions most favorable to compete with foreign companies within the domestic market the synchronization has significant impact on sectors for both mature products and technologically advanced products it is thus necessary to reexamine the role of import substitution practices under the new context of globalization and in conjunction with exports

economic liberalization and the computer industry comparing outcomes in brazil and mexico abstract market liberalization has been carried out by many developing countries in the hopes of stimulating trade investment and technology transfer in order to analyze the impacts of liberalization on a specific industry sector this paper compares the experiences of brazil and mexico in liberalizing the computer industry in the 1990s the authors conclude that liberalization leads to lower prices and more rapid diffusion of computer use throughout the economy but at a cost to domestic computer firms who were harmed by foreign competition both countries saw an increase in computer production but mexico s production was mainly for export to the united states while brazil was producing for the domestic market the differences between outcomes in the two countries have been determined more by environmental factors than by the nature and pace of liberalization

the alliances of spin offs versus start ups social ties in the genesis of post soviet alliances this paper links the alliance strategy of emergent firms to the structural relations in the network of new firm organizers data gathered in russia from 1991 to 1993 on nine post soviet commodity exchange markets demonstrate how the difference in internal social structure between spin off and startup exchanges shapes the strategy of their inter firm networks and initial performance the way in which managers come together structures their diversity and openness to the outside environment in turn the social structure internal to the firm affects the ran ge and scope of their ties to other organizations i show how the high range of overlap among the ties between spin off founders has a more concentrated connection to the outside environment than the exchanges created by more loosely linked startup founders the relational costs of the more concentrated ties increases the cost of search however it lowers the cost of malfeasance thus the model suggested proposes that the relative advantage of investing in relational capital is a double edged sword which poses constraints along with its particular advantages finally the model also brings to question the relative merits of concentrated alliances supposedly advantageous to new firms in particular by suggesting that conditions of transition and institutional instability may under cut the relative advantage of familiarity and specialization found in western settings

physician agency and adoption of generic pharmaceuticals i examine physician agency in health care services in the context of the choice between brand name and generic pharmaceuticals i examine micro panel data from japan where physicians can legally make profits by prescribing and dispensing drugs the results indicate that physicians often fail to internalize patient costs explaining why cheaper generics are infrequently adopted doctors respond to markup differentials between the two versions indicating another agency problem however generics markup advantages are short lived which limits their impact on increasing generic adoption additionally state dependence and heterogeneous doctor preferences affected generics adoption policy makers can target these factors to improve static efficiency

securities analysts and incumbent response to radical technological change evidence from digital photography and internet telephony a large body of research has explored the factors that impede established firms responses to radical technological changes while it is widely acknowledged that managers face pressures from financial markets to choose strategies that maximize shareholder value little work in the technological change literature has considered the possible influences of public equity markets and the securities analysts who mediate them on incumbent firms challenged with technological change in this paper i begin to address the topic by empirically exploring how securities analysts react to the different strategies undertaken by incumbent firms faced with radical technological change i study the question in two settings the shift to digital technology in photography and the advent of voice over internet protocol voip technology in wireline telecommunications i find evidence that analysts are more attentive and positive toward incumbents strategies that extend and preserve the existing technology than toward strategies that respond directly to the new technology in these settings analysts largely ignore incumbents strategies that directly incorporate the new technology for several years following the discontinuity this study provides insights into the nature and direction of analysts reactions to firms strategies in the context of technological change and is a first step toward better understanding of the potential role of analysts and financial markets in incumbent adaptation

aggregation and imperfect competition on the existence of equilibrium we present a new approach to the theory of imperfect competition and apply it to study price competition among differentiated products the central result provides general conditions under which there exists a pure strategy price equilibrium for any number of firms producing any set of products this includes products with multi dimen sional attributes in addition to the proof of existence we provide conditions for uniqueness our analysis covers location models the characteristics approach and probabilistic choice together in a unified framework to prove existence we employ aggregation theorems due to prekopa 1971 and borell 1975 our companion paper caplin and nalebuff 1991 introduces these theorems and develops the application to super majority voting rules we present a new approach to the theory of imperfect competition and apply it to study price competition among differentiated products the central result is that there exists a pure strategy price equilibrium for any number of firms producing any set of products in addition to the proof of existence we provide conditions for uniqueness our model both unites diverse strands of the earlier literature and opens up uncharted areas for future analysis in particular we expand the traditional one dimensional framework to allow for multi dimen sional product differentiation our approach involves twin restrictions on consumer preferences one on individuals preferences the other on the distribution of preferences across society these are generalizations of the restrictions supporting 64 majority rule presented in caplin and nalebuff 1988 to prove existence we apply a new technique of aggregation this technique is valuable in a variety of other problems in the companion paper we use the aggregation result to generalize our earlier work on 64 majority rule and to characterize the relationship between the distribution of human capital and the distribution of income caplin and nalebuff 1991 there are additional applications in statistics and in search theory we begin with a brief review of the early literature on imperfect competition describing in more detail the existence problem and previous solutions section 3 presents our twin assumptions and shows that they cover many standard cases in section 4 we introduce the aggregation theorem and use it in the analysis of demand functions the proof of existence of equilibrium is in section

product differentiation and oligopoly in international markets the case of the u s automobile industry this paper develops and estimates a model of the u s automobile industry on the demand side a discrete choice model is adopted that is estimated using micro data from the consumer expenditure survey the estimation results are used in conjunction with population weights to derive aggregate demand on the supply side the automobile industry is modelled as an oligopoly with product differentiation equilibrium is characterized by the first order conditions of the profit maximizing firms the estimation results are used in counterfactual simulations to investigate two trade policy issues the effects of the ver and exchange rate pass through

the role of firm characteristics in pharmaceutical product launches this paper examines the determinants of new pharmaceutical launches since 1980 in the g7 nations using discrete time hazard models despite the obvious incentive to amortize the large sunk costs of drug development over many markets entry occurs in only 4 of the opportunities the results indicate that firm characteristics such as domestic status and experience in the local market are important in explaining product launches in addition to market characteristics also the interaction between the innovating firm and target country is a critical component of profitability new drugs are 1 5 times more likely to be launched in markets that share a border or a language of a drug company s country of headquarters even for multinational firms the effect of competition depends on the characteristics of both the potential entrant and the incumbents domestic entrants prefer to compete with domestic incumbents although this is an industry with the potential for ubiquitous licensing and low transportation costs the specific match quality between the innovating firm and market conditions remains an important determinant of entry